75957-53-8

Usage

Uses

Used in Pharmaceutical Industry:
Boc-Val-Tyr-OBzl is used as a building block in peptide synthesis for the development of new drugs. Its unique structure allows for the creation of custom peptide sequences that can be tailored to target specific biological processes or diseases, making it a valuable tool in the discovery and design of innovative pharmaceuticals.
Used in Research Applications:
In the realm of scientific research, Boc-Val-Tyr-OBzl is employed as a component in the study of biological processes. Its role in peptide synthesis enables researchers to explore the interactions between peptides and other biomolecules, furthering our understanding of complex biological systems and potentially leading to new therapeutic strategies.
Used in Peptide Synthesis:
Boc-Val-Tyr-OBzl is used as a versatile component in peptide synthesis for creating custom peptide sequences. Its protective groups facilitate controlled peptide assembly, allowing chemists to construct peptides with specific properties and functions. This capability is crucial for both research and pharmaceutical applications, where the development of novel peptide-based therapeutics and the study of peptide interactions are of significant interest.

Upstream product

• 13734-41-3 t-Boc-L-valine 
• 53587-11-4 L-tyrosine benzyl ester p-toluenesulfonate 
• 3392-12-9 Boc-Val-ONSu 
• 42406-77-9 L-tyrosine benzyl ester 

Downstream Products

• 77456-95-2 N^α-tert-butoxycarbonylvalyltyrosine 
• 271600-77-2 benzyl ester of N^α,N^G,N^G-tribenzyloxycarbonyl-argynyl-N-prolyl-β-benzylaspartyl-valyl-tyrosine 
• 271600-76-1 Z₃ArgGlyAsp(OBzl)ValTyrOBzl 
• 95548-52-0 2>-thymopentin (Arg-Pro-Asp-Val-Tyr) 
• 75957-54-9 N^α-t-butoxycarbonyl-β-benzyl-L-aspartyl-L-valyl-L-tyrosine benzyl ester 
• 437754-03-5 (S)-3-(4-Hydroxy-phenyl)-2-[(S)-2-(6-iodo-hexanoylamino)-3-methyl-butyrylamino]-propionic acid benzyl ester 
• 180078-20-0 6-bromohexanoyl-L-valinyl-L-tyrosine benzyl ester 
• 180078-22-2 10S-isopropyl-8,11-dioxo-2-oxa-9,12-diaza-bicyclo[13.2.2]nonadeca-1⁽¹⁸⁾,15⁽¹⁹⁾,16-triene-13S-carboxylic acid benzyl ester 
• 180078-21-1 9S-isopropyl-7,10-dioxo-2-oxa-8,11-diaza-bicyclo[12.2.2]octadeca-1⁽¹⁷⁾,14⁽¹⁸⁾,15-triene-12S-carboxylic acid benzyl ester 
• 437754-02-4 4-bromobutyryl-L-valinyl-L-tyrosine benzyl ester 
• 180078-19-7 5-bromopentanoyl-L-valinyl-L-tyrosine benzyl ester 
• 80622-00-0 H-Val-Tyr-OBzl*TFA 
• 80621-99-4 H-Val-Tyr-OBzl 
• 3061-91-4 L-valyl-L-tyrosine 

Relevant academic research and scientific papers

Sequential Intermolecular Radical Addition and Reductive Radical Cyclization of Tyrosine and Phenylalanine Derivatives with Alkenes via Photoinduced Decarboxylation: Access to Ring-Constrained γ-Amino Acids

Sequential radical addition to alkenes and reductive radical cyclization of phenylalanine and tyrosine derivatives via photoinduced decarboxylation furnished ring-constrained γ-amino acids under mild conditions. A variety of alkenes such as acrylamides and acrylic esters could be employed in the photoinduced radical cascade cyclization. The yields of the ring-constrained γ-amino acids are dependent on the electron-accepting ability and steric hindrance of the alkene used. The proposed sequential reaction can also be applied for direct tethering of dipeptides to yield unique ring-constrained tetrapeptides.

Tetrahydro-β-carboline-3-carboxyl-thymopentin: A nano-conjugate for releasing pharmacophores to treat tumor and complications

To improve the therapeutic efficacy of cancer patients a novel conjugate of thymopentin (TP5) and (1S,3S)-1-methyl-tetrahydro-β-carboline-3-carboxylic acid (MTC) was presented. In water and mouse plasma MTCTP5 forms the nanoparticles of 14-139 nm in diameter, the suitable size for delivery in blood circulation. In mouse plasma MTCTP5 releases MTC, while in the presence of trypsin MTCTP5 releases MTC and TP5. On mouse and rat models the MTCTP5 dose dependently slows down the tumor growth, inhibits inflammatory response and blocks thrombosis. The anti-tumor activity as well as the anti-inflammation activity and anti-thrombotic activity of MTCTP5 are 100 fold and 10 fold higher than those of MTC, respectively, which are attributed to the fact that it down-regulates the plasma levels of TNF-α and IL-8 of the treated animals. The immunology enhancing activities in vitro and in vivo of MTCTP5 are similar to those of TP5, which is attributed to the fact that MTCTP5 up-regulates the plasma levels of IL-2 and CD4 as well as down-regulates the plasma level of CD8 of the treated animals. The plasma alanine transaminase, aspartate transaminase and creatinine assays indicate that MTCTP5 therapy does not injure the liver and the kidney of the animals. The survival time of MTCTP5 treated mice is significantly longer than that of TP5 treated mice.

Conformationally constrained macrocycles that mimic tripeptide β-strands in water and aprotic solvents

The β-strand conformation is unknown for short peptides in aqueous solution, yet it is a fundamental building block in proteins and the crucial recognition motif for proteolytic enzymes that enable formation and turnover of all proteins. To create a gener

Immunoactive peptides: VI. Synthesis of new analogs of thymopoietin

A new scheme for preparing a pentapeptide of thymopoietin (ArgLysAspValTyr, TP-5) is proposed, featuring a versatile combination of the maximal and minimal protection principles. The scheme was used to prepare the Gly2, Pro2, Ala3, and Arg2, Ala3 analogs of TP-5.

PEPTIDE DERIVATIVES AND ANGIOTENSIN IV RECEPTOR AGONIST

Short-chain peptide derivatives acting on angiotensin IV receptor at low concentrations. Because of agonistically acting on angiotensin IV receptor, the novel peptide derivatives of the present invention represented by the following formula (1) are useful as remedies for various diseases in which angiotensin IV participates:

A Convenient Synthesis of Thymopentin

A convenient and economical solution phase synthesis of thymopentin in which the side chain of tyrosine is left unprotected is reported.